Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2010

View Archived Issues

Aeolus invited to submit full proposal to BARDA for further development AEOL-10150

Premier Research begins phase II trial of Vantia's VA-111913 for menstrual cramps

Biogen Idec submits MAA in Europe and NDA in Canada for Fampridine-PR

Cytheris initiates phase IIa INSPIRE 2 trial of CYT107 in HIV-infected patients

Infinity outlines key objectives for 2010

Life Technologies to acquire AcroMetrix

Synexus finalizes its acquisition of ClinPharm

FDA approves Diagnostic Hybrids' D3 FastPoint L-DFA RSV/MPV identification kit

Celera grants UCSF license to develop test for KIF6 gene variant

Quest Diagnostics launches molecular blood test for detection of colorectal cancer

SciClone and Sigma-Tau report initial results from clinical study of Zadaxin and Focetria

FDA grants orphan drug status to Allon Therapeutics' neuroprotective drug davunetide for PSP

Laromustine/cytarabine activity in relapsed acute myeloid leukemia to be studied further

Phase IIa MLN-3897 trial suggests CCR-1 antagonism is ineffective to treat RA

NVP-BEZ235 may enhance activity of cytotoxic agents in sarcoma

Ixabepilone not active in childhood solid tumors

Transdermal patch effectively delivers teriparatide in postmenopausal women with osteoporosis

Evotec and CHDI Foundation extend collaboration to fight Huntington's disease

AstraZenenca and CrystalGenomics form collaboration to develop antibacterial agents

Genentech describes novel checkpoint kinase inhibitors as oncolytics

Novel janus kinase inhibitors disclosed by AstraZeneca

Bionomics describes potassium channel blockers for inflammatory and autoimmune diseases

NicOx presents novel antagonists of angiotensin AT2 receptor as antihypertensive agents

Sumavel DosePro launched in the U.S. for acute migraine and cluster headaches

GlaxoSmithKline presents PI3Kdelta inhibitors for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...